Comments
Loading...
Abbott Laboratories Analyst Ratings and Price Targets | NYSE:ABT | Benzinga
Abbott Laboratories Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Abbott Laboratories Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Raymond James
Piper Sandler
RBC Capital
Wells Fargo
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Abbott Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | — | Raymond James | Jayson Bedford69% | $132 → $142 | Maintains | Outperform | Get Alert |
| 04/17/2025 | Buy Now | — | Piper Sandler | Adam Maeder62% | $133 → $145 | Reiterates | Overweight → Overweight | Get Alert |
| 04/17/2025 | Buy Now | — | RBC Capital | Shagun Singh56% | $140 → $145 | Maintains | Outperform | Get Alert |
| 04/17/2025 | Buy Now | — | Wells Fargo | Lawrence Biegelsen47% | $136 → $147 | Maintains | Overweight | Get Alert |
| 04/17/2025 | Buy Now | — | Morgan Stanley | David Lewis73% | $117 → $127 | Maintains | Equal-Weight | Get Alert |
| 04/17/2025 | Buy Now | — | Barclays | Matt Miksic67% | $158 → $159 | Maintains | Overweight | Get Alert |
| 04/17/2025 | Buy Now | — | Stifel | Rick Wise72% | $135 → $145 | Maintains | Buy | Get Alert |
| 04/17/2025 | Buy Now | — | Jefferies | Matthew Taylor70% | $135 → $137 | Maintains | Hold | Get Alert |
| 03/10/2025 | Buy Now | — | B of A Securities | Travis Steed59% | $133 → $150 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | — | Citigroup | Joanne Wuensch74% | $135 → $160 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | — | Goldman Sachs | David Roman35% | $138 → $154 | Maintains | Buy | Get Alert |
| 01/27/2025 | Buy Now | — | Barclays | Matt Miksic67% | $149 → $158 | Maintains | Overweight | Get Alert |
| 01/23/2025 | Buy Now | — | RBC Capital | Shagun Singh56% | $135 → $135 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2025 | Buy Now | — | Wells Fargo | Lawrence Biegelsen47% | $133 → $136 | Maintains | Overweight | Get Alert |
| 01/23/2025 | Buy Now | — | Stifel | Rick Wise72% | $130 → $135 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | — | UBS | Danielle Antalffy60% | $146 → $148 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | — | RBC Capital | Shagun Singh56% | $135 → $135 | Reiterates | Outperform → Outperform | Get Alert |
| 11/05/2024 | Buy Now | — | Barclays | Matt Miksic67% | $143 → $149 | Maintains | Overweight | Get Alert |
| 10/17/2024 | Buy Now | — | Bernstein | Lee Hambright60% | $133 → $138 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | — | UBS | Danielle Antalffy60% | $143 → $146 | Maintains | Buy | Get Alert |
| 10/17/2024 | Buy Now | — | Jefferies | Matthew Taylor70% | $120 → $125 | Maintains | Hold | Get Alert |
| 10/17/2024 | Buy Now | — | Mizuho | Anthony Petrone64% | $115 → $130 | Maintains | Neutral | Get Alert |
| 10/17/2024 | Buy Now | — | Piper Sandler | Adam Maeder62% | $131 → $133 | Maintains | Overweight | Get Alert |
| 10/17/2024 | Buy Now | — | Morgan Stanley | David Lewis73% | $107 → $117 | Maintains | Equal-Weight | Get Alert |
| 10/14/2024 | Buy Now | — | Raymond James | Jayson Bedford69% | $122 → $129 | Maintains | Outperform | Get Alert |
| 10/08/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $125 → $130 | Maintains | Outperform | Get Alert |
| 10/08/2024 | Buy Now | — | Oppenheimer | Suraj Kalia55% | → $130 | Initiates | → Outperform | Get Alert |
| 10/01/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar49% | $120 → $124 | Maintains | Outperform | Get Alert |
| 09/26/2024 | Buy Now | — | Jefferies | Raj Denhoy75% | $120 → $120 | Reiterates | Hold → Hold | Get Alert |
| 09/19/2024 | Buy Now | — | Piper Sandler | Adam Maeder62% | → $131 | Initiates | → Overweight | Get Alert |
| 08/27/2024 | Buy Now | — | Jefferies | Raj Denhoy75% | $112 → $120 | Maintains | Buy | Get Alert |
| 08/22/2024 | Buy Now | — | Citigroup | Joanna Wiensch64% | $119 → $127 | Maintains | Buy | Get Alert |
| 07/29/2024 | Buy Now | — | Barclays | Matt Miksic67% | $140 → $143 | Maintains | Overweight | Get Alert |
| 07/02/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar49% | $125 → $120 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $125 → $125 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2024 | Buy Now | — | Goldman Sachs | David Roman35% | → $121 | Initiates | → Buy | Get Alert |
| 05/22/2024 | Buy Now | — | Citigroup | Joanna Wiensch64% | $128 → $119 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | — | Barclays | Matt Miksic67% | $141 → $140 | Maintains | Overweight | Get Alert |
| 04/18/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $128 → $125 | Maintains | Outperform | Get Alert |
| 04/04/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar49% | $120 → $125 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | — | Citigroup | Joanne Wuensch74% | $126 → $128 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $128 → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/26/2024 | Buy Now | — | Barclays | Matt Miksic67% | $133 → $141 | Maintains | Overweight | Get Alert |
| 01/25/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $128 → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/25/2024 | Buy Now | — | Citigroup | Joanne Wuensch74% | $123 → $126 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | — | Raymond James | Jayson Bedford69% | $124 → $127 | Maintains | Outperform | Get Alert |
| 01/11/2024 | Buy Now | — | RBC Capital | Shagun Singh56% | $119 → $128 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | — | Raymond James | Jayson Bedford69% | $110 → $124 | Maintains | Outperform | Get Alert |
| 12/13/2023 | Buy Now | — | Wells Fargo | Lawrence Biegelsen47% | $116 → $121 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | — | Citigroup | Joanne Wuensch74% | $122 → $123 | Maintains | Buy | Get Alert |
| 10/19/2023 | Buy Now | — | Barclays | Matt Miksic67% | $132 → $133 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | — | Morgan Stanley | David Lewis73% | $112 → $107 | Maintains | Equal-Weight | Get Alert |
| 10/19/2023 | Buy Now | — | Wells Fargo | Lawrence Biegelsen47% | $136 → $116 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | — | Raymond James | Jayson Bedford69% | $123 → $110 | Maintains | Outperform | Get Alert |
| 10/02/2023 | Buy Now | — | Citigroup | Joanne Wuensch74% | $130 → $122 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | — | Barclays | Matt Miksic67% | $127 → $132 | Maintains | Overweight | Get Alert |
| 07/21/2023 | Buy Now | — | Morgan Stanley | David Lewis73% | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/21/2023 | Buy Now | — | Mizuho | Anthony Petrone64% | $110 → $115 | Assumes | Neutral → Neutral | Get Alert |
| 07/21/2023 | Buy Now | — | Wolfe Research | Mike Polark53% | — | Upgrade | Underperform → Peer Perform | Get Alert |
| 05/30/2023 | Buy Now | — | Morgan Stanley | David Lewis73% | → $112 | Assumes | → Equal-Weight | Get Alert |
| 04/20/2023 | Buy Now | — | UBS | Matthew Korn47% | $117 → $130 | Maintains | Buy | Get Alert |
| 04/20/2023 | Buy Now | — | Raymond James | Jayson Bedford69% | $116 → $123 | Maintains | Outperform | Get Alert |
| 04/20/2023 | Buy Now | — | Barclays | Matt Miksic67% | $125 → $127 | Maintains | Overweight | Get Alert |
| 04/20/2023 | Buy Now | — | Citigroup | Joanne Wuensch74% | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | — | BTIG | Ryan Zimmerman70% | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | — | Raymond James | Jayson Bedford69% | $123 → $116 | Maintains | Outperform | Get Alert |
| 04/10/2023 | Buy Now | — | Wells Fargo | Lawrence Biegelsen47% | $140 → $136 | Maintains | Overweight | Get Alert |
| 04/05/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen66% | $140 → $136 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | — | UBS | Danielle Antalffy60% | → $117 | Assumes | → Buy | Get Alert |
| 01/27/2023 | Buy Now | — | Barclays | Matt Miksic67% | $122 → $125 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | — | BTIG | Marie Thibault62% | $120 → $125 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | — | Stifel | Rick Wise72% | $110 → $125 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | — | Raymond James | Jayson Bedford69% | $109 → $123 | Maintains | Outperform | Get Alert |
| 01/26/2023 | Buy Now | — | Bernstein | Lee Hambright60% | $125 → $132 | Maintains | Outperform | Get Alert |
| 01/25/2023 | Buy Now | — | Wolfe Research | Mike Polark53% | $92 → $107 | Maintains | Underperform | Get Alert |
| 01/24/2023 | Buy Now | — | Mizuho | Anthony Petrone64% | $105 → $110 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | — | Morgan Stanley | Cecilia Furlong51% | $117 → $133 | Maintains | Overweight | Get Alert |
| 01/04/2023 | Buy Now | — | Barclays | Matt Miksic67% | $114 → $122 | Maintains | Overweight | Get Alert |
| 12/13/2022 | Buy Now | — | TD Cowen | Joshua Jennings54% | $130 → $130 | Maintains | Outperform | Get Alert |
| 12/12/2022 | Buy Now | — | Citigroup | Joanne Wuensch74% | $114 → $125 | Maintains | Buy | Get Alert |
| 10/26/2022 | Buy Now | — | Mizuho | Anthony Petrone64% | → $105 | Initiates | → Neutral | Get Alert |
| 10/21/2022 | Buy Now | — | Barclays | Matt Miksic67% | $118 → $114 | Maintains | Overweight | Get Alert |
| 10/21/2022 | Buy Now | — | Raymond James | Jayson Bedford69% | $117 → $109 | Maintains | Outperform | Get Alert |
| 10/20/2022 | Buy Now | — | Citigroup | Joanna Wiensch64% | $117 → $114 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | — | BTIG | Marie Thibault62% | $123 → $120 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | — | Stifel | Rick Wise72% | $126 → $110 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | — | JP Morgan | Robbie Marcus66% | $125 → $118 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | — | Morgan Stanley | Cecilia Furlong51% | $126 → $117 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | — | RBC Capital | Shagun Singh56% | $132 → $126 | Maintains | Outperform | Get Alert |
| 10/19/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar49% | $114 → $110 | Maintains | Outperform | Get Alert |
| 10/18/2022 | Buy Now | — | Barclays | Matt Miksic67% | → $118 | Initiates | → Overweight | Get Alert |
| 10/17/2022 | Buy Now | — | BTIG | Ryan Zimmerman70% | $126 → $123 | Maintains | Buy | Get Alert |
| 10/12/2022 | Buy Now | — | Jefferies | Matthew Taylor70% | → $110 | Initiates | → Hold | Get Alert |
| 10/11/2022 | Buy Now | — | Morgan Stanley | Cecilia Furlong51% | $132 → $126 | Maintains | Overweight | Get Alert |
| 10/10/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen66% | $150 → $140 | Maintains | Overweight | Get Alert |
| 10/09/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen66% | → $150 | Maintains | Overweight | Get Alert |
| 10/05/2022 | Buy Now | — | Citigroup | Joanna Wiensch64% | $123 → $117 | Maintains | Buy | Get Alert |
| 08/19/2022 | Buy Now | — | BTIG | Marie Thibault62% | → $140 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen66% | $155 → $150 | Maintains | Overweight | Get Alert |
| 07/28/2022 | Buy Now | — | Argus Research | David Toung71% | $150 → $135 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Abbott Laboratories (ABT) stock?
The latest price target for Abbott Laboratories (NYSE:ABT) was reported by Raymond James on April 17, 2025. The analyst firm set a price target for $142.00 expecting ABT to rise to within 12 months (a possible 10.89% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abbott Laboratories (ABT)?
The latest analyst rating for Abbott Laboratories (NYSE:ABT) was provided by Raymond James, and Abbott Laboratories maintained their outperform rating.
When was the last upgrade for Abbott Laboratories (ABT)?
The last upgrade for Abbott Laboratories happened on July 21, 2023 when Wolfe Research raised their price target to N/A. Wolfe Research previously had an underperform for Abbott Laboratories.
When was the last downgrade for Abbott Laboratories (ABT)?
There is no last downgrade for Abbott Laboratories.
When is the next analyst rating going to be posted or updated for Abbott Laboratories (ABT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Abbott Laboratories (ABT) correct?
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $132.00 to $142.00. The current price Abbott Laboratories (ABT) is trading at is $128.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
